Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sherbenou, Daniel
NCT04925193: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma	Active, not recruiting	2	18	US	Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone	University of Colorado, Denver, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)	Multiple Myeloma in Relapse	08/24	11/25
NCT06429449: Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia	Recruiting	1	30	US	Venetoclax, Venclexta, Venclyxto, Azacitidine, Onureg, Vidaza, Mitoxantrone, Novantrone	University of Colorado, Denver, The Leukemia and Lymphoma Society	Leukemia, Myeloid Leukemia, Monocytic Leukemia	12/26	11/27
CaMMouflage, NCT05722418: CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma	Recruiting	1	50	US	CB-011, Cyclophosphamide, Fludarabine	Caribou Biosciences, Inc.	Relapsed/Refractory Multiple Myeloma	02/25	02/27
20-1319.cc, NCT05287568: CC-486 and Venetoclax for Acute Myeloid Leukemia	Recruiting	1	35	US	Venetoclax, ABT-199, Abbvie, CC-486	University of Colorado, Denver, Bristol-Myers Squibb	AML	03/27	03/29
Spiegel, Jay
NCT06553872: Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL	Recruiting	2	60	US	Pirtobrutinib, Jaypirca, Brexucabtagene Autoleucel, Tecartus	H. Lee Moffitt Cancer Center and Research Institute, Bankhead-Coley Florida Biomedical Research Program, Eli Lilly and Company	Mantle Cell Lymphoma	08/29	08/29
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma	Recruiting	2	123	US	Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)	CARGO Therapeutics	Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)	09/25	12/26
GLEAN-1, NCT04735471: A Phase 1 Study of ADI-001 in B Cell Malignancies	Active, not recruiting	1	78	US	ADI-001, Fludarabine, Cyclophosphamide	Adicet Therapeutics	Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin	07/25	12/27
CaMMouflage, NCT05722418: CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma	Recruiting	1	50	US	CB-011, Cyclophosphamide, Fludarabine	Caribou Biosciences, Inc.	Relapsed/Refractory Multiple Myeloma	02/25	02/27
NCT02129543: Immune Reconstitution in Stem Cell Transplant Recipients	Recruiting	N/A	700	US	Blood Draw	University of Miami	Cancer	12/25	12/25